Thompson Davis & CO. Inc. Has $1.25 Million Stake in GeneDx Holdings Corp. $WGS

Key Points

• Thompson Davis & CO. Inc. has reduced its holdings in GeneDx by 33.0%, now owning a total of 14,150 shares, which makes up 1.0% of their portfolio.
• Several institutional investors, including Vanguard Group and Summit Partners, have significantly increased their positions in GeneDx, indicating a growing interest in the stock.
• Insider sales have seen CEO Katherine Stueland and CFO Kevin Feeley sell notable amounts of stock, resulting in a combined sale of 22,411 shares valued at over $2 million in the last quarter.

Thompson Davis & CO. Inc. lessened its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 33.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,150 shares of the company's stock after selling 6,980 shares during the quarter. GeneDx makes up 1.0% of Thompson Davis & CO. Inc.'s investment portfolio, making the stock its 12th largest holding. Thompson Davis & CO. Inc. owned 0.05% of GeneDx worth $1,253,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Sterling Capital Management LLC lifted its holdings in shares of GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after buying an additional 316 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of GeneDx during the 4th quarter valued at about $35,000. GAMMA Investing LLC lifted its holdings in shares of GeneDx by 151.7% during the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after buying an additional 264 shares during the last quarter. Comerica Bank acquired a new stake in shares of GeneDx during the 4th quarter valued at about $50,000. Finally, US Bancorp DE lifted its holdings in shares of GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock valued at $50,000 after buying an additional 548 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Stock Performance

NASDAQ WGS traded down $5.25 during trading on Tuesday, hitting $120.65. The company's stock had a trading volume of 848,639 shares, compared to its average volume of 1,066,527. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average price of $89.46 and a 200 day moving average price of $86.14. The firm has a market cap of $3.47 billion, a P/E ratio of 2,413.00 and a beta of 2.02. GeneDx Holdings Corp. has a 52 week low of $28.86 and a 52 week high of $127.55.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.10 by $0.40. The company had revenue of $102.69 million for the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. GeneDx has set its FY 2025 guidance at EPS. Equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

WGS has been the subject of several research reports. Jefferies Financial Group upgraded GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a report on Friday, May 9th. Guggenheim reiterated a "buy" rating and set a $115.00 price target (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. TD Securities reduced their target price on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Wells Fargo & Company boosted their target price on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 30th. Finally, Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $101.63.

Insider Activity at GeneDx

In related news, CEO Katherine Stueland sold 9,657 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $90.94, for a total value of $878,207.58. Following the completion of the transaction, the chief executive officer directly owned 4,940 shares in the company, valued at approximately $449,243.60. This represents a 66.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kevin Feeley sold 5,278 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $93.00, for a total value of $490,854.00. Following the completion of the transaction, the chief financial officer owned 3,392 shares of the company's stock, valued at $315,456. The trade was a 60.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,411 shares of company stock worth $2,085,051. Company insiders own 29.60% of the company's stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.